Obesity clinical trials

The registry lists 11,522 studies for Obesity across more than 10 countries. 2,033 are recruiting or about to start. 7,587 of them are mainly about Obesity (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 7 narrower conditions too, such as Pediatric Obesity: 13,385 studies, 2,346 open.

ClinicalTrials.gov finds 15,150 studies for Obesity. How that becomes 11,510 here

This page counts the studies the registry files under Obesity, and those it files under no condition that list Obesitythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

15,150Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−1,856Filed under a narrower condition, counted on its own pagePediatric Obesity 779 · Obesity, Morbid 668 · Obesity, Abdominal 173 · Prader-Willi Syndrome 110 · Obesity Hypoventilation Syndrome 61 · Pregnancy in Obesity 34 · 1 more
−142List Obesity as a condition, but the registry did not file them under itMost often written as “Sarcopenic Obesity” (31), “Obesity Prevention” (23), and “Hypothalamic Obesity” (15). The registry filed them under other conditions only, most often Motor Activity (18) and Sexual Infantilism (15).
−1,642Match it another way496 name it in the title, 36 in a keyword, and 1,110 by a synonym or other text the search reads.
11,510The count on this page125 of them list Obesity in their own words; the registry filed them under no condition.

Status

Completed: 7,190
Recruiting: 1,336
Status unknown: 1,012
Active, not recruiting: 599
Not yet recruiting: 588
Terminated: 418

Phase

Phase 2: 863
Phase 1: 738
Phase 3: 604
Phase 4: 503
Early Phase 1: 108

Where

United States: 4,817
China: 597
Canada: 574
France: 475
United Kingdom: 452
Spain: 387

Who runs them

Novo Nordisk A/S (205) · Eli Lilly and Company (117) · Mayo Clinic (106) · University of Colorado, Denver (105) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (104) · Washington University School of Medicine (85) · University of Copenhagen (84) · The Miriam Hospital (79)

What is being tested here

Drugs under test in Obesity studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Semaglutide	65	45	138
Tirzepatide	59	28	103
Zenagamtide	17	14	24
Eloralintide	14	8	22
Metformin	13	12	79
Berobenatide	10	11	20
Mazdutide	10	4	18
Cagrilintide	9	15	36
Probiotic	9	1	33
Maridebart cafraglutide	9	11	28

Drug classes tested here GLP-1 receptor agonists 130 open · Mineralocorticoid receptor antagonists (MRAs) 6 open · SGLT2 inhibitors 5 open · Opioid antagonists 4 open · Stimulants 3 open

Coming up

173phase 3 studies under way

838studies finish main data collection within a year47 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity · Phase 3 · Eli Lilly and Company
Nov 2026A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight · Phase 3 · Eli Lilly and Company
Nov 2026A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight · Phase 3 · Eli Lilly and Company
Nov 2026Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. · Phase 3 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Dec 2026The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) · Phase 3 · University of Virginia
Dec 2026A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity · Phase 3 · Fujian Shengdi Pharmaceutical Co., Ltd.
Dec 2026A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy · Phase 3 · Fujian Shengdi Pharmaceutical Co., Ltd.
Dec 2026A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use · Phase 3 · Vanda Pharmaceuticals
Dec 2026Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus · Phase 3 · HK inno.N Corporation
Jan 2027PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis · Phase 3 · University of Alabama at Birmingham

Who these studies take

Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger. 168 (13%) take children under 18. 132 (10%) are for women only and 17 (1%) for men only; 491 (37%) take healthy volunteers.

Recruiting studies that take each age, of 1,336
Age	Women	Men
10	92 (7%)	86 (6%)
18	1,015 (76%)	932 (70%)
30	1,114 (83%)	1,023 (77%)
40	1,123 (84%)	1,034 (77%)
50	1,083 (81%)	1,015 (76%)
65	901 (67%)	859 (64%)
75	577 (43%)	547 (41%)
85	418 (31%)	391 (29%)

Across all 11,522 studies, recruiting or not: 70% stop at 75 or younger and 56% at 65; 16% take children; 14% are for women only and 5% for men only; 47% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Obesity studies take

Of 439 phase 1 interventional studies under Obesity, half reached primary completion within 11 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	11 mo6–24 · 439 studies	9 mo5–15 · 334 studies	32 mo12–57 · 105 studies
Phase 1/2	27 mo14–36 · 62 studies	—	31 mo14–36 · 39 studies
Phase 2	16 mo10–35 · 308 studies	12 mo8–18 · 176 studies	35 mo15–57 · 132 studies
Phase 2/3	47 mo30–53 · 36 studies	—	47 mo30–53 · 33 studies
Phase 3	24 mo18–34 · 261 studies	21 mo18–27 · 198 studies	36 mo24–56 · 63 studies
Phase 4	31 mo15–51 · 210 studies	—	32 mo15–52 · 190 studies
Interventional, no phase	22 mo10–42 · 3,843 studies	12 mo6–27 · 163 studies	23 mo10–43 · 3,680 studies
Observational	39 mo17–96 · 836 studies	25 mo9–45 · 45 studies	40 mo17–106 · 791 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out